Mortality in Patients with Interstitial Lung Diseases Hospitalized by Severe or Critical COVID-19

Overview

Journal BMC Pulm Med

Publisher Biomed Central

Specialty Pulmonary Medicine

Date 2023 Oct 12

PMID 37828511

Authors

Ana Karem S Pruneda

Jose Omar Barreto-Rodriguez

Moises Selman

Fortunato Juarez-Hernandez

Ivette Buendia-Roldan

Affiliations

Soon will be listed here.

Abstract

Background: Since the first case of severe COVID-19, its effect on patients with previous interstitial lung disease (ILD) has been uncertain. We aimed to describe baseline clinical characteristics in ILD patients hospitalized by critical COVID and compare mortality during hospitalization.

Methods: We studied patients with ILD with COVID-19 and a control group matched by age, 1:2 ratio with COVID-19 without previous lung disease. On admission, laboratory tests and sociodemographic variables were evaluated. We evaluated patients critically ill and compared baseline characteristics and mortality in each group. Additionally, we performed a sub-analysis of ILD patients who died versus survivors.

Results: Forty-one patients and 82 controls were analyzed. In the group of ILD with COVID-19 there was a predominance of women (65 versus 33%: p < 0.001); lower leukocytes (9 ± 6 versus 11 ± 7, p = 0.01) and neutrophils (8 ± 5 versus 10 ± 6, p = 0.02). The most common ILD was secondary to autoimmune diseases. Patients with ILD and critical COVID-19 showed a significantly higher mortality compared with those without previous ILD (63 versus 33%, p = 0.007). Patients who died in this group had higher BMI (28 ± 6 versus 25 ± 4 kg/m, p = 0.05), less extended hospital stay (20 ± 17 versus 36 ± 27 days, p = 0.01), and fewer days of evolution (9 ± 7 versus 16 ± 16, p = 0.05).

Conclusions: We found higher mortality in patients with ILD with critical COVID-19. Higher BMI and comorbidities were present in the non-survivors.

References

Guiot J, Henket M, Frix A, Delvaux M, Denis A, Giltay L . Single-center experience of patients with interstitial lung diseases during the early days of the COVID-19 pandemic. Respir Investig. 2020; 58(6):437-439. PMC: 7501770. DOI: 10.1016/j.resinv.2020.08.006. View

Huang H, Zhang M, Chen C, Zhang H, Wei Y, Tian J . Clinical characteristics of COVID-19 in patients with preexisting ILD: A retrospective study in a single center in Wuhan, China. J Med Virol. 2020; 92(11):2742-2750. PMC: 7322991. DOI: 10.1002/jmv.26174. View

Dutt N, Shishir S, Chauhan N, Jalandra R, Kuwal A, Garg P . Mortality and Its Predictors in COVID-19 Patients With Pre-existing Interstitial Lung Disease. Cureus. 2022; 14(8):e27759. PMC: 9448685. DOI: 10.7759/cureus.27759. View

Naqvi S, Lakhani D, Sohail A, Maurer J, Sofka S, Sarwari A . Patients with idiopathic pulmonary fibrosis have poor clinical outcomes with COVID-19 disease: a propensity matched multicentre research network analysis. BMJ Open Respir Res. 2021; 8(1). PMC: 8354761. DOI: 10.1136/bmjresp-2021-000969. View

Sharma A, Farouk I, Lal S . COVID-19: A Review on the Novel Coronavirus Disease Evolution, Transmission, Detection, Control and Prevention. Viruses. 2021; 13(2). PMC: 7911532. DOI: 10.3390/v13020202. View

Zhao J, Metra B, George G, Roman J, Mallon J, Sundaram B . Mortality among Patients with COVID-19 and Different Interstitial Lung Disease Subtypes: A Multicenter Cohort Study. Ann Am Thorac Soc. 2022; 19(8):1435-1437. PMC: 9353962. DOI: 10.1513/AnnalsATS.202202-137RL. View

Esposito A, Menon A, Ghosh A, Putman R, Fredenburgh L, El-Chemaly S . Increased Odds of Death for Patients with Interstitial Lung Disease and COVID-19: A Case-Control Study. Am J Respir Crit Care Med. 2020; 202(12):1710-1713. PMC: 7737588. DOI: 10.1164/rccm.202006-2441LE. View

Hu B, Guo H, Zhou P, Shi Z . Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2020; 19(3):141-154. PMC: 7537588. DOI: 10.1038/s41579-020-00459-7. View

Lee H, Choi H, Yang B, Lee S, Park T, Park D . Interstitial lung disease increases susceptibility to and severity of COVID-19. Eur Respir J. 2021; 58(6). PMC: 8061231. DOI: 10.1183/13993003.04125-2020. View

10.

Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H . Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8(5):475-481. PMC: 7102538. DOI: 10.1016/S2213-2600(20)30079-5. View

11.

Drake T, Docherty A, Harrison E, Quint J, Adamali H, Agnew S . Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. Am J Respir Crit Care Med. 2020; 202(12):1656-1665. PMC: 7737581. DOI: 10.1164/rccm.202007-2794OC. View

12.

Wang Y, Hao Y, Hu M, Wang Y, Yang H . Interstitial lung disease independently associated with higher risk for COVID-19 severity and mortality: A meta-analysis of adjusted effect estimates. Int Immunopharmacol. 2022; 111:109088. PMC: 9325673. DOI: 10.1016/j.intimp.2022.109088. View

13.

Mancilla-Galindo J, Vera-Zertuche J, Navarro-Cruz A, Segura-Badilla O, Reyes-Velazquez G, Tepepa-Lopez F . Development and validation of the patient history COVID-19 (PH-Covid19) scoring system: a multivariable prediction model of death in Mexican patients with COVID-19. Epidemiol Infect. 2020; 148:e286. PMC: 7729170. DOI: 10.1017/S0950268820002903. View

14.

Jiang F, Deng L, Zhang L, Cai Y, Cheung C, Xia Z . Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19). J Gen Intern Med. 2020; 35(5):1545-1549. PMC: 7088708. DOI: 10.1007/s11606-020-05762-w. View

15.

Cilli A, Hanta I, Uzer F, Coskun F, Sevinc C, Pinar Deniz P . Characteristics and outcomes of COVID-19 patients with IPF: A multi-center retrospective study. Respir Med Res. 2022; 81:100900. PMC: 8890788. DOI: 10.1016/j.resmer.2022.100900. View

16.

Gallay L, Uzunhan Y, Borie R, Lazor R, Rigaud P, Marchand-Adam S . Risk Factors for Mortality after COVID-19 in Patients with Preexisting Interstitial Lung Disease. Am J Respir Crit Care Med. 2020; 203(2):245-249. PMC: 7874431. DOI: 10.1164/rccm.202007-2638LE. View